FDA Approves Eli Lilly's Foundayo as Second Oral GLP-1 Agonist for Obesity Treatment
Here's what it means for you.
New obesity treatment options could reshape health benefits and wellness strategies in corporate environments.
What happened
The U.S. FDA approved Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for obesity treatment.
The Context
- Second oral GLP-1 drug: Foundayo follows Novo Nordisk's Wegovy pill, providing a more accessible alternative to injectable treatments.
- Cost-effective: Priced at $149 per month for self-pay patients, it targets adults with obesity or overweight, aiming for sustainable weight reduction.
- Rapid approval: The FDA's expedited review took just 50 days, marking the fastest approval for a new molecular entity since 2002.
The Number
This is the average weight reduction at the highest dose after 72 weeks, a significant metric in evaluating treatment effectiveness for obesity.
Takeaway
As demand for obesity treatments rises, expect increased competition and innovation in the pharmaceutical landscape.
Insights by A47 Intelligence
Global markets, investing, and macroeconomics from a premier financial newsroom.
"Bloomberg is respected for in-depth financial reporting and data-driven analysis."
— A47 Editor
Novo VP Weighs In on Approval of Lilly’s Obesity Pill
Jamey Millar, executive vice president of US operations at Novo Nordisk, commented on the recent FDA approval of Eli Lilly's weight-loss pill, Foundayo, during an appearance on Bloomberg The Close. This approval marks a significant milestone for Lill...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Lilly’s Obesity Pill Approval Kicks Off New Front in Weight-Loss Drug Wars
Eli Lilly has received FDA approval for its obesity pill, Foundayo, marking a significant entry into the competitive weight-loss drug market, where it will compete directly with Novo Nordisk's offerings. This approval is seen as a pivotal moment for ...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
The FDA has approved Eli Lilly's new weight-loss pill, Foundayo, which positions the company to compete directly with Novo Nordisk's Wegovy in the rapidly expanding multibillion-dollar obesity drug market. This approval marks a significant milestone ...
Medical reporting with scientific depth and public service tone.
"NPR is a nonprofit media organization offering thoughtful, in-depth journalism and storytelling, often with a liberal or progressive slant."
— A47 Editor
The FDA approves a new obesity pill, giving patients another option
The FDA has approved a new daily obesity pill named Foundayo, which has received a fast track designation, providing patients with an alternative to injectable obesity medications like Wegovy. This approval marks a significant development in the phar...
Emerging technologies, digital transformation, IT, and cultural impact of tech.
"WIRED covers the intersection of technology, culture, and politics with a progressive, forward-looking editorial stance."
— A47 Editor
FDA Approves Eli Lilly’s GLP-1 Pill
The FDA has approved Eli Lilly's once-daily obesity pill, Foundayo, marking it as the second GLP-1 medication to receive such approval, following Novo Nordisk's Wegovy. This approval is a significant milestone in the pharmaceutical industry, particul...
News from the United States including domestic politics, society, and culture.
"The Guardian is known for its progressive editorial stance and in-depth analysis, often advocating for social justice, environmental issues, and liberal values."
— A47 Editor
US approves new oral weight-loss pill developed by Eli Lilly
The US Food and Drug Administration (FDA) has approved a new oral weight-loss medication called Foundayo, developed by Eli Lilly. This approval marks the second GLP-1 drug in pill form to enter the market, following Novo Nordisk's Wegovy, which recei...
Top international stories selected by The Guardian editors.
"The Guardian is known for its progressive editorial stance and in-depth analysis."
— A47 Editor
US approves new oral weight-loss pill developed by Eli Lilly
The US Food and Drug Administration (FDA) has approved a new oral weight-loss medication called Foundayo, developed by Eli Lilly. This approval marks the second GLP-1 drug in pill form to enter the market, following Novo Nordisk's Wegovy, which recei...
Reports on science policy, discoveries, and public debate in the scientific realm.
"The Guardian’s science section is known for thoughtful and critical reporting on global research, ethics, and public understanding of science."
— A47 Editor
US approves new oral weight-loss pill developed by Eli Lilly
The US Food and Drug Administration (FDA) has approved a new oral weight-loss medication called Foundayo, developed by Eli Lilly. This approval marks the second GLP-1 drug in pill form to enter the market, following Novo Nordisk's Wegovy, which recei...
Canadian and international health news, medicine, public policy, and research.
"Global News is a mainstream Canadian outlet generally considered to have a centrist editorial stance, covering news with a focus on factual reporting and national interest."
— A47 Editor
U.S. FDA approves Eli Lilly’s GLP-1 oral weight-loss pill
The U.S. FDA has approved Eli Lilly's GLP-1 oral weight-loss pill, marking one of the fastest approval times for any drug, with the decision made within just 50 days of the company's application. This approval signifies a significant advancement in w...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
FDA Approves Eli Lilly’s Weight Loss Pill—Second Weight GLP-1 Drug In Pill Form
The FDA has approved Eli Lilly's weight loss pill, Foundayo, marking it as the second GLP-1 drug available in pill form aimed at treating obesity. This approval is expected to facilitate long-term weight loss when combined with diet and exercise.
Public health news, medical research, and wellness coverage.
"NBC News is a mainstream outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
FDA approves lower-cost daily weight loss pill from Eli Lilly
The FDA has approved a new daily weight loss pill named Foundayo, developed by Eli Lilly, marking it as the second oral GLP-1 medication to enter the market after Novo Nordisk's Wegovy. This approval is significant as it offers a lower-cost option fo...
National headlines across the United States including breaking stories and societal issues.
"NBC News is a mainstream media outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
FDA approves lower-cost daily weight loss pill from Eli Lilly
The FDA has approved a new daily weight loss pill named Foundayo, developed by Eli Lilly, marking it as the second oral GLP-1 medication to enter the market after Novo Nordisk's Wegovy. This approval is significant as it offers a lower-cost option fo...